Sugi Predict

Sugi Predict / Compounds / SCHEMBL204082

SCHEMBL204082

SCHEMBL204082

O=C(O)c1coc2cc(O)ccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 1/20 0.54
▸ ALDH1A1 P00352 6/20 0.51
▸ KDM4E B2RXH2 4/20 0.51
▸ NPC1 O15118 3/20 0.51
▸ RAB9A P51151 3/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51
▸ POLB P06746 1/20 0.51
▸ CA12 O43570 3/20 0.50
▸ CA7 P43166 3/20 0.50
▸ HPGD P15428 3/20 0.50
▸ HSD17B10 Q99714 3/20 0.50
▸ MAOB P27338 2/20 0.50
▸ AKR1B10 O60218 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ TTR P02766 1/20 0.50
▸ ESR1 P03372 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ ALDH2 P05091 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11353008 0.88 MAOB (0.63) PIM1ALDH1A1KDM4ENPC1RAB9A
SCHEMBL29630236 0.85 SIRT1 (0.66) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL3377499 0.85 SIRT1 (0.66) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL17338672 0.84 ALDH1A1 (0.51) PIM1ALDH1A1KDM4ENPC1RAB9A
SCHEMBL23359886 0.80 KEAP1 (0.46) PIM1ALDH1A1KDM4ENPC1RAB9A
SCHEMBL31704456 0.80 KDM4E (0.50) PIM1ALDH1A1KDM4ENPC1RAB9A
SCHEMBL18530849 0.80 SMN1; SMN2 (0.59) PIM1ALDH1A1KDM4ENPC1RAB9A
SCHEMBL29933509 0.80 SMN1; SMN2 (0.59) PIM1ALDH1A1KDM4ENPC1RAB9A
SCHEMBL23320560 0.80 KDM4E (0.50) PIM1ALDH1A1KDM4ENPC1RAB9A
SCHEMBL743289 0.80 CA12 (0.53) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4055014-B1 PYRROLIDINE AND PIPERIDINE COMPOUNDS YUHAN CORP (KR) 2025-04-30 — — EP disclosed
CN-114867719-B Pyrrolidine and piperidine compounds 柳韩洋行 2024-06-25 — — CN disclosed
US-11655235-B2 Pyrrolidine and piperidine compounds YUHAN CORPORATION (KR) 2023-05-23 — — US disclosed
EP-4055014-A1 PYRROLIDINE AND PIPERIDINE COMPOUNDS Yuhan Corporation (KR) 2022-09-14 — — EP disclosed
CN-114867719-A Pyrrolidine and piperidine compounds 柳韩洋行 2022-08-05 — — CN disclosed
US-20210147386-A1 PYRROLIDINE AND PIPERIDINE COMPOUNDS YUHAN CORPORATION (KR) 2021-05-20 — — US disclosed
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 — — US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 — — US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 — — EP disclosed
EP-2743268-A2 Fused cyclic compounds as GPR40 receptor modulators Takeda Pharmaceutical Company Limited (JP) 2014-06-18 — — EP disclosed
EP-2041123-B1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-02-01 — — EP disclosed
US-8088821-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-03 — — US disclosed
EP-2125782-B1 ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES NOVARTIS AG (CH) 2011-08-03 — — EP disclosed
EP-2248812-A2 Fused cyclic compounds as GPR40 receptor modulators Takeda Pharmaceutical Company Limited (JP) 2010-11-10 — — EP disclosed
US-20100197761-A1 Fused cyclic compounds YASUMA TSUNEO 2010-08-05 — — US disclosed
US-7732626-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-08 — — US disclosed
US-20100004312-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 — — US disclosed
EP-2041123-A2 FUSED CYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2009-04-01 — — EP disclosed
WO-2008101905-A1 ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES NOVARTIS AG (CH) 2008-08-28 — — WO disclosed
WO-2008001931-A2 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 PIM1 445/4885ALDH1A1 2300/4885KDM4E 843/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 PIM1 445/4885ALDH1A1 2300/4885KDM4E 843/4885
US-20100004312-A1 FUSED CYCLIC COMPOUNDS GPR119, GLP1R, GPR65 PIM1 3706/4885ALDH1A1 3122/4885KDM4E 3536/4885
US-11655235-B2 Pyrrolidine and piperidine compounds FAP, APC, VHL PIM1 1984/4885ALDH1A1 439/4885KDM4E 1644/4885
US-20100197761-A1 Fused cyclic compounds GPR119, GLP1R, GPR65 PIM1 3706/4885ALDH1A1 3122/4885KDM4E 3536/4885
US-20210147386-A1 PYRROLIDINE AND PIPERIDINE COMPOUNDS FAP, APC, VHL PIM1 1984/4885ALDH1A1 439/4885KDM4E 1644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.